Expert insights. Personalized for you.
Life science Related Topics 
McKinsey
OCTOBER 28, 2021
As cloud technology matures, life-sciences companies are generating new paths to business value beyond the cost efficiencies that cloud migrations typically target. Insights on Life Sciences Medical products Pharmaceuticals Cloud computing
McKinsey
MAY 31, 2022
Insights on Life Sciences PharmaceuticalsPfizer’s Chief Digital and Technology Officer explains how digital is transforming her organization’s ability to bring new medicines to patients at speed and at scale.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Frost & Sullivan
JANUARY 31, 2022
31, 2022 – The post COVID-19 pandemic recovery and other geopolitical events in 2021 has left the healthcare & life sciences industry in a remarkable position to be ready for 2022 and beyond. San Antonio, TX, – Jan.
Frost & Sullivan
AUGUST 9, 2021
As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.
Frost & Sullivan
AUGUST 9, 2021
As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.
LaVoie Health Science Blog
JULY 16, 2021
Interviews with our senior practice managers about issues of important to life science innovators. As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors.
Frost & Sullivan
AUGUST 5, 2021
LifeSphere supports hundreds of global life sciences companies to accelerate development, maintain compliance, and streamline collaboration between cross-functional teams. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases
Frost & Sullivan
JANUARY 11, 2022
January 11, 2022 – Frost & Sullivan analyzed global digital transformation services in the life sciences industry and, based on its findings, recognizes Capgemin i with the 2021 Global Company of the Year Award for digital transformation services within life sciences.
Frost & Sullivan
FEBRUARY 8, 2021
To help companies identify new avenues for top-line growth and plan for a more fruitful 2021, Frost & Sullivan’s team of industry experts have compiled a complimentary insight: Top 8 Growth Opportunities in the Healthcare and Life Sciences Industry for 2021 – What You Need to Know Now.
McKinsey
JUNE 10, 2022
Insights on Life Sciences BiotechnologyFrom 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.
McKinsey
MARCH 21, 2022
Pharmaceutical and life sciences companies can unlock new opportunities, help underserved patients, and build a cycle of trust. Insights on Life Sciences Health care reform Pharmaceuticals
McKinsey
MAY 31, 2022
Insights on Life Sciences Pharmaceuticals Biotechnology Artificial IntelligenceBiopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help ensure their investments flourish at a time of fierce competition.
McKinsey
APRIL 8, 2022
Harnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease. Insights on Life Sciences Biotechnology Innovation
McKinsey
JUNE 9, 2022
Insights on Life Sciences BiotechnologyEmerging biotechnology companies are less satisfied than large pharmaceutical companies with their contract research organizations (CROs). How can CROs raise their game with this key segment?
McKinsey
DECEMBER 21, 2021
Insights on Life Sciences PharmaceuticalsThe COVID-19 pandemic has prompted pharma companies to rethink their organizational strategies. A survey of executives suggests where value might lie.
McKinsey
APRIL 15, 2022
Insights on Life Sciences Health care services Health Care PharmaceuticalsHealth data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing our understanding of disease.
McKinsey
MAY 11, 2022
Insights on Life Sciences Health Care BiotechnologyBiotech stocks have taken a hit, but the sector will probably rebound. Companies can navigate the downturn by scrutinizing cash management and financing and rethinking paths to long-term value creation.
McKinsey
MARCH 23, 2022
Insights on Life Sciences Biotechnology Globalization StrategyEstablishing an international presence with a first launch is a challenge, but learning from others’ experiences can help biotechs avoid missteps and maximize their chances of success.
McKinsey
SEPTEMBER 24, 2021
Insights on Life Sciences Medical products Digital marketing AnalyticsDigital marketing offers medtech companies powerful ways to personalize engagement with healthcare professionals and respond to their changing needs.
McKinsey
MARCH 15, 2022
Insights on Life Sciences Pharmaceuticals AnalyticsAs pharma companies apply advanced analytics to generate new types of evidence, how do they decide which use cases to target and how to scale them up across the business?
McKinsey
DECEMBER 3, 2021
The United Kingdom is Europe’s leading biotech hub in breakthrough life-sciences start-ups. Insights on Life Sciences Pharmaceuticals Medical products United KingdomHow is this hub maturing relative to its global peers, and what lies ahead on the road to sustainable scale?
McKinsey
MAY 10, 2022
Insights on Life Sciences PharmaceuticalsLeading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains and builds long-term capabilities at the same time.
McKinsey
SEPTEMBER 16, 2021
Insights on Life Sciences PharmaceuticalsBy rethinking the approach to regulatory submissions, pharma companies can reduce timelines and increase their chances of successful product approvals.
McKinsey
DECEMBER 2, 2021
Insights on Life Sciences Medical products PharmaceuticalsBiopharma companies should consider a new, integrated approach to evidence-generation strategies to better demonstrate the value of therapies to all stakeholders.
McKinsey
NOVEMBER 29, 2021
Insights on Life Sciences Pharmaceuticals Supply chain managementClinical trials have increased in number and have become more complex, decentralized, and patient-centric. While this puts pressure on clinical drug supply, it also brings new opportunities.
McKinsey
MARCH 23, 2022
Insights on Life Sciences Pharmaceuticals Manufacturing StrategyCOVID-19 disruptions have led many pharmas to reassess their manufacturing networks and strategies. We share four ways that pharma companies can optimize manufacturing and avoid common pitfalls.
McKinsey
OCTOBER 29, 2021
Insights on Life Sciences Pharmaceuticals Medical products ChinaChinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.
McKinsey
SEPTEMBER 23, 2021
Insights on Life Sciences Pharmaceuticals Supply chain managementPharmaceutical supply chains have become global and complex. With more outsourcing, new modalities, and novel ways to reach patients, it’s critical to ensure that they can withstand shocks.
McKinsey
MARCH 15, 2022
Insights on Life Sciences Health Care High Tech & Internet Pharmaceuticals DigitalOur eHealth Monitor report shows solid uptakes of telemedicine and consumer health apps. But e-prescriptions, health data exchange, and patient use of electronic health records are lagging behind.
McKinsey
MAY 6, 2022
Insights on Life Sciences PharmaceuticalsTransformations often struggle to scale up and make change stick. To achieve lasting impact, high-performing R&D organizations pay heed to the five outcomes that matter most.
McKinsey
JANUARY 10, 2022
Insights on Life Sciences Pharmaceuticals Leadership StrategyPharmaceutical and medical-device companies can get the most value from “smart quality” processes enabled with new technologies by adopting a holistic approach to building culture and capabilities.
McKinsey
MARCH 29, 2022
Insights on Life Sciences PharmaceuticalsViral-vector gene therapies are here to stay. Keeping pace with increasing demand requires consideration of challenges, the potential for standardization, and strategizing for accelerating patient access.
McKinsey
OCTOBER 4, 2021
Insights on Life Sciences Pharmaceuticals Public healthAngela Hwang, Pfizer’s head of biopharmaceuticals, talks about breaking new ground when the pressure is on—and how having a deep company heritage can help.
McKinsey
OCTOBER 5, 2021
Insights on Life Sciences Pharmaceuticals Public health LeadershipAmid the COVID-19 crisis, the CEO of the Coalition for Epidemic Preparedness Innovations explains his five-year strategy that includes reducing vaccine timelines.
McKinsey
DECEMBER 1, 2021
The first female CEO of the United Kingdom’s Royal Academy of Engineering reflects on the evolving role of engineering in a dematerializing world, its vital role in science and sustainability—and collaborating with a Formula One world champion. Insights on Life Sciences
McKinsey
SEPTEMBER 20, 2021
Insights on Life Sciences Pharmaceuticals Public healthAngela Hwang, Pfizer’s head of biopharmaceuticals, talks about breaking new ground when the pressure is on—and how having a deep company heritage can help.
Frost & Sullivan
MARCH 16, 2022
Best Practice Awards Energy & Environment Best Practices Healthcare & Life Sciences Best Practices ICT Best Practices Mobility Best Practices News Press Releases Best Practices Awards Digital Transformation
Frost & Sullivan
MARCH 14, 2022
Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases Asia-Pacific Best Practices Awards Entrepreneurial Company of the Year Frost & Sullivan Awards Insilico MedicineSAN ANTONIO , Mar.
McKinsey
SEPTEMBER 15, 2021
Moderna’s delivery of a COVID-19 vaccine comes on the heels of revolutionary science that may accelerate innovation across the industry well into the future. Insights on Life Sciences Pharmaceuticals Public health Health care services Managing in Uncertainty Innovation
Frost & Sullivan
SEPTEMBER 16, 2021
It employs deep learning algorithms, and different data science and data knowledge types to generate meaningful real-world evidence (RWE), helping to build a holistic view of the patient journey. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases
94 
Let's personalize your content